Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain

Clinical Pharmacokinetics

Volumn 49, Issue 10, 2010, Pages 671-682

  Xu, Xu Steven ^a   Smit, Johan W ^b   Lin, Rachel ^a   Stuyckens, Kim ^b   Terlinden, Rolf ^c   Nandy, Partha ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c GRÜNENTHAL GMBH   (Germany)

Author keywords

Opioid analgesics; Pharmacokinetic modelling; pharmacokinetics; Population pharmacokinetics; Research and development; Tapentadol

Indexed keywords

BILIRUBIN; TAPENTADOL;

ADULT; AGED; ARTICLE; BIOEQUIVALENCE; CHRONIC PAIN; COMPUTER PROGRAM; CREATININE CLEARANCE; DEMOGRAPHY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG MECHANISM; DRUG RELEASE; FEMALE; HEALTH STATUS; HUMAN; IMMEDIATE DRUG RELEASE; MAJOR CLINICAL STUDY; MALE; PAIN; PRIORITY JOURNAL; SIMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANALGESICS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; COMPUTER SIMULATION; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MONTE CARLO METHOD; PAIN; PHENOLS; YOUNG ADULT;

EID: 77956365463     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11535390-000000000-00000     Document Type: Article

References (30)

1. Tzschentke TM, Christoph T, Kogel B, et al. (-)-(1R,2R)-3-(3- dimethylamino-thyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 7; 323 (1): 265-276
2. Nucynta™ (tapentadol) immediate release oral tablets: US prescribing information. Raritan (NJ): Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2008 Nov [online]. Available from URL: http://www. accessdata. fda. gov/drugsatfda-docs/label/2008/022304s000lbl-v2. pdf [Accessed 2010 Jun 18]
3. Kleinert R, Lange C, Steup A, et al. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study. Anesth Analg 2008 Dec; 107 (6): 2048-2055
4. Weber H, Hallmann C, Steup A, et al. Efficacy and safety of tapentadol HCl in patients with pain after bunionectomy [abstract]. J Pain 2006; 7 (4): S3
5. Hartrick C, Van Hove I, Stegmann J-U, et al. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active-and placebo-controlled study. Clin Ther 2009; 31 (2): 260-271
6. Stegmann J-U, Weber H, Steup A, et al. The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery. Curr Med Res Opin 2008; 24 (11): 3185-3196
7. Afilalo M, Oh C, Okamoto A, et al. Tapentadol immediate release compared with oxycodone immediate release for the relief of moderate-to-severe pain in patients with end stage joint disease [abstract]. J Pain 2008; 9 (4): 32
8. Oh C, Upmalis D, Okamoto A, et al. Efficacy of tapentadol immediate release in patients with pain after bunionectomy [abstract]. J Pain 2008; 9 (4): 33
9. Upmalis D, Okamoto A, Oh C, et al. Symptoms of opioid withdrawal after discontinuation of tapentadol immediate release, an analgesic with mu-opioid receptor agonism [abstract]. J Pain 2008; 9 (4): 29
10. Pinn S. Tapentadol a 'realistic alternative' to strong opioids for severe pain. Br J Hosp Med (Lond) 2008 Sep; 69 (9): 499
11. Thompson CA. Tapentadol approved as pain reliever. Am J Health Syst Pharm 2009 Jan 1; 66 (1): 8
12. Terlinden R, Ossig J, Fliegert F, et al. Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. Eur J Drug Metab Pharmacokinet 2007 Jul-Sep; 32 (3): 163-169
13. Terlinden R, Ossig J, Fliegert F, et al. Pharmacokinetics, excretion, and me-tabolism of tapentadol HCl, a novel centrally acting analgesic, in healthy subjects [abstract]. J Pain 2007; 7 (4): S26
14. Ahn JE, Karlsson MO, Dunne A, et al. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn 2008 Aug; 35 (4): 401-421
15. Byon W, Fletcher CV, Brundage RC. Impact of censoring data below an ar-bitrary quantification limit on structural model misspecification. J Pharma-cokinet Pharmacodyn 2008 Feb; 35 (1): 101-116
16. Center for Drug Evaluation and Research, US FDA. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products-general considerations [revision 1]. Rockville (MD): FDA 2003 Mar [online]. Available from URL: http://www. fda. gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM070124. pdf [Accessed 2010 Jun 18]
17. Jonsson EN, Karlsson MO. Xpose: an S-Plus based population pharmaco-kinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999 Jan; 58 (1): 51-64
18. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9 (4): 503-512
19. Bruno R,Vivier N,Vergniol JC, et al. Apopulation pharmacokinetic modelfor docetaxel (Taxotere): model building and validation. J Pharmacokinet Bio-pharm 1996; 24 (2): 153-172
20. Preston SL, Drusano GL, Berman AL, et al. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob Agents Chemother 1998; 42 (5): 1098-1104
21. Duffull SB, Aarons L. Development of a sequential linked pharmacokinetic and pharmacodynamic simulation model for ivabradine in healthy volunteers. Eur J Pharm Sci 2000; 10 (4): 275-284
22. Deurenberg P, Weststrate JA, Seidell JC. Body mass index as a measure of body fatness: age-and sex-specific prediction formulas. Br J Nutr 1991; 65: 105-114
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 (1): 31-41
24. Kirkpatrick CM, Duffull SB, Begg EJ. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. Br J Clin Pharmacol 1999 Jun; 47 (6): 637-643
25. Han PY, Duffull SB, Kirkpatrick CMJ, et al. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 2007 Nov; 82 (5): 505-508
26. Sparreboom A, Wolff AC, Mathijssen RHJ, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 2007; 25 (30): 4707-4713
27. Mathijssen RH, Sparreboom A. Influence of lean body weight on anticancer drug clearance. Clin Pharmacol Ther 2009 Jan; 85 (1): 23; author reply 24
28. Reidenberg MM, Drayer DE. Alteration of drug-protein binding in renal disease. Clin Pharmacokinet 1984 Jan; 9 Suppl. 1: 18-26
29. Atkinson Jr AJ, Ruo TI, Frederiksen MC. Physiological basis of multi-compartmental models of drug distribution. Trends Pharmacol Sci 1991 Mar; 12 (3): 96-101
30. Odar-Cederlof I, Borga O. Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding. Eur J Clin Pharmacol 1974; 7 (1): 31-37